Everything below concerns drug affinity complex. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
== Gel Preparation Methods == The process of gel formation involves finding a balance between the concentrations of the gelator and the solvent. When adding a gelator to the solvent, the mixture remains in liquid state. As the concentration of the gelator increases to a certain critical concentration (gelling point), gelation occurs through swelling to form the semi-solid gel. Further increasing the concentration of the gelator beyond the gelling point will increase gel viscosity. The exact gelling point varies depending on the properties of the gelator and the solvent, such as structure uniformity, molecular weight of the polymer, and flexibility of the polymer chain. Generally, gels are prepared by firstly dissolving the soluble excipients in the solvent. The solution is then mixed using a mechanical stirrer. After that, the gelator is added slowly to the stirred mixture in order to avoid aggregation. Then, the mixture is continuously stirred until the polymer dissolves and a gel gradually forms. The gel is allowed to settle for one to two days before the final consistency of the gel can be reached. The exact method of preparing gels depends on the properties of the formulation ingredients.
A capillary is a small blood vessel, from 5 to 10 micrometres in diameter, and is part of the microcirculation system. Capillaries are microvessels and the smallest blood vessels in the body. They are composed of only the tunica intima (the innermost layer of an artery or vein), consisting of a thin wall of simple squamous endothelial cells. They are the site of the exchange of many substances from the surrounding interstitial fluid, and they convey blood from the smallest branches of the arteries (arterioles) to those of the veins (venules). Other substances which cross capillaries include water, oxygen, carbon dioxide, urea, glucose, uric acid, lactic acid and creatinine. Lymph capillaries connect with larger lymph vessels to drain lymphatic fluid collected in microcirculation.
=== Scanning electron microscopy === Scanning electron microscopy is used to view dinosaur eggshell under even greater magnification than is possible with light microscopy. However, this does not mean that scanning electron microscopy is necessarily the superior research method. Since both techniques provide differing amounts and types of information they can be used together synergistically to provide a more complete understanding of the specimen under scrutiny. Eggshell specimens best suited for scanning electron microscopy are those recently broken because such a break will usually occur along the plane of the eggshell's calcite crystal lattice. First, a small specimen would be covered with a very thin layer of gold or platinum. The specimen would then be bombarded with electrons. The electrons bounce back off the metal and due to their small size, can be used to form a detailed image of the specimen.
In 1953, changes in political leadership on both sides shifted the dynamic of the Cold War. Dwight D. Eisenhower was inaugurated president that January. During the last 18 months of the Truman administration, the American defense budget had quadrupled, and Eisenhower moved to reduce military spending by a third while continuing to fight the Cold War effectively. Joseph Stalin died in 1953. Nikita Khrushchev eventually won the ensuing power struggle by the mid-1950s. In 1956, he denounced Joseph Stalin and proceeded to ease controls over the party and society (de-Stalinization).
=== Colombia === The Military Forces of Colombia issues the Campaign Ration (Spanish: Ración de Campaña), a dark olive green plastic bag weighing between 1092 and 1205 grams and providing 3,097 to 3,515 kcal (12,960 to 14,710 kJ). Inside are the retort pouch main courses and supplements needed by a soldier for one day. The individual meals, which cater to South American tastes, consist of a breakfast, a lunch, and a main meal (Tamal, envueltos, lentils with chorizo, arvejas con carne, garbanzo beans a la madrileña, arroz atollado, ajiaco con pollo, and sudado con papas y carne). The ration also includes bread products, beverage mixes, candy and accessories. All items except the beverage mixes require no further preparation and can be eaten either hot or cold. The beverage powders must be mixed with hot or cold water before consumption. Each ration also contains raw sugar, a can of condensed milk, sandwich cookies, sweetened and thickened cream spread, hard candy or caramels, peanuts or trail mix or 25 g of roasted almonds, instant coffee, salt, paper towels, a plastic spoon, 2 water purification tablets, and a multivitamin tablet.
Sources: en.wikipedia.org
NatB acetylates N-terminal proteins starting with methionine (iMet) followed by or amidic amino acids, making the target pool to be MD, ME, MN and MQ. Almost 100% of all the proteins that are target substrates of NatB are N-terminally acetylated, which is a unique feature of NatB compared to other NATs. Finding substrates and proteins that are N-terminally acetylated by NatB has been studied in yeast and humans in order to understand the biological function of NatB. In yeast, lack of N-terminal acetylation activity by NatB has an effect on actin and tropomyosin interactions. The NF-κB subunit p65 has also been proposed to be a target protein in humans, as well as tropomyosin 1. NatB also seems to potentially regulate the Set-COMPASS subunit protein Swd1 by N-terminal acetylation, and therefore NatB could regulate H3K4 methylation together with NatA. NatB might also regulate NAD+ metabolism in yeast, where knockout of nat3Δ (NAA25) and mdm20Δ (NAA20) decreased the levels of the nicotinamide mononucleotide adenylyltransferase (Nmnat) proteins Nma1 and Nma2. NATs belongs to the GCN5 related N-acetyltransferases (GNAT) superfamily. N-terminal acetylation is the process of adding an acetyl group during or after protein synthesis.
== Applications == Affibody molecules can be used for protein purification, enzyme inhibition, research reagents for protein capture and detection, diagnostic imaging and targeted therapy. The second generation of Affibody molecule, ABY-025, binds selectively to HER2 receptors with picomolar affinity. These Affibody molecules are in clinical development for tumor diagnosis. Anti-HER2 Affibody molecule, fused with albumin binding domain (ABD), denoted as ABY-027, labeled with Lutetium-177 provided reduction of renal and hepatic uptake of radioactivity in mice xenografts.. Further preclinical research evaluated an optimised version of the same ABD-fused Affibody, reporting an improved therapeutic effect in combination with trastuzumab. In October 2025, a refined variant of the ABD-fused Affibody molecule targeting HER2, radiolabelled with Lutetium-177, entered clinical trials to assess its safety, biodistribution and tolerability in patients with metastatic breast cancer. Recently, anti-ZEGFR Affibody ZEGFR:2377 labeled with technetium-99m was successfully used to visualize ZEGR expressing tumor in mice xenograft also.
In addition to power and ground, these provide connections for data-in, data-out, clock and sometimes a strobe signal. These are connected in a daisy chain, which allows individual LEDs in a long LED strip light to be easily controlled by a microcontroller. Data sent to the first LED of the chain can control the brightness and color of each LED independently of the others. They are used where a combination of maximum control and minimum visible electronics are needed such as strings for Christmas and LED matrices. Some even have refresh rates in the kHz range, allowing for basic video applications. These devices are known by their part number (WS2812 being common) or a brand name such as NeoPixel. Filament An LED filament consists of multiple LED chips connected in series on a common longitudinal substrate that forms a thin rod reminiscent of a traditional incandescent filament. These are being used as a low-cost decorative alternative for traditional light bulbs that are being phased out in many countries. The filaments use a rather high voltage, allowing them to work efficiently with mains voltages. Often a simple rectifier and capacitive current limiting are employed to create a low-cost replacement for a traditional light bulb without the complexity of the low voltage, high current converter that single die LEDs need. Usually, they are packaged in bulb similar to the lamps they were designed to replace, and filled with inert gas at slightly lower than ambient pressure to remove heat efficiently and prevent corrosion.
== Bonding == Some models of bonding for desmosines, created through the study of bovine ligament elastin, suggest a combination of desmosine and secondary cross-linking to bind together peptide chains. This model has desmosine bonding near an alanine on the peptide chain, then to 3 other amino acids on the 2 peptide chains, despite being able to bond to up to 4 chains. It has been suggested that the secondary cross-linking occurs with either desmosine or lysinonorleucine, which maintains an alpha helix conformation in alanine rich sections on peptides. Both isodesmosine and desmosine can have similar bonding sites in elastin, though it rarely shown this way in nature. They more often will appear in close proximity to each other on the peptide chain.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.